ONO-1110 + Placebo

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Postherpetic Neuralgia

Conditions

Postherpetic Neuralgia

Trial Timeline

Feb 12, 2025 → Aug 31, 2026

NCT ID

NCT06708416

About ONO-1110 + Placebo

ONO-1110 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Postherpetic Neuralgia. The current trial status is active. This product is registered under clinical trial identifier NCT06708416. Target conditions include Postherpetic Neuralgia.

What happened to similar drugs?

4 of 8 similar drugs in Postherpetic Neuralgia were approved

Approved (4) Terminated (1) Active (4)

✅QUTENZAAstellas PharmaApproved

✅Etoricoxib + PlaceboMerckApproved

✅Lyrica (pregabalin) + PlaceboPfizerApproved

✅pregabalinPfizerApproved

🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3

🔄Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3

🔄pregabalinPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06752603	Phase 2	Recruiting	Apr 2, 2025	Aug 1, 2026	Hunner Type Interstitial Cystitis
NCT06752590	Phase 2	Recruiting	Mar 26, 2025	Sep 1, 2026	Fibromyalgia
NCT06708416	Phase 2	Active	Feb 12, 2025	Aug 31, 2026	Postherpetic Neuralgia
NCT06805565	Phase 2	Active	Jan 16, 2025	Oct 31, 2026	Social Anxiety Disorder (SAD)
NCT06792136	Phase 2	Active	Jan 16, 2025	Aug 31, 2026	Major Depressive Disorder (MDD

Competing Products

20 competing products in Postherpetic Neuralgia

See all competitors

Product	Company	Stage	Hype Score
QUTENZA	Astellas Pharma	Approved	43
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
MK-8291 + Placebo	Merck	Phase 1	29
Etoricoxib + Placebo	Merck	Approved	39
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
MK0686	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
Lyrica (pregabalin) + Placebo	Pfizer	Approved	43
RN624 + RN624 + Placebo	Pfizer	Phase 2	35
T-62	Pfizer	Phase 2	27
pregabalin + pregabalin/PF-00489791 + Placebo	Pfizer	Phase 2	35
PH-797804 + Placebo	Pfizer	Phase 2	35
Placebo + Pregabalin + Pregabalin + Pregabalin	Pfizer	Phase 3	40
pregabalin	Pfizer	Phase 3	40
pregabalin	Pfizer	Approved	35
T-62 Dose 1 + T-62 Dose 2	Pfizer	Phase 2	27
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID	Haisco Pharmaceutical Group	Phase 3	40
Levetiracetam	UCB	Phase 2	35